Dedicated to Improving the Lives of Patients with Food Allergies and Other Immunological Diseases

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they developed a novel class of immunotherapy that aims to activate the immune system of patients through the skin.

Food allergies are serious medical conditions that occur when the body has a specific immune response to certain foods. The body’s immune response can be severe and life threatening, such as anaphylaxis. In people with food allergies, the immune system mistakenly responds to a certain food as if it were harmful. Anaphylaxis is a sudden and severe allergic reaction that may cause death.

Pioneering a New Class of Immunotherapy through a Novel Technology Platform, Viaskin

We are developing Viaskin, a novel technology platform that potentially has broad applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, which aims to deliver biologically active compounds to the immune system through intact skin.

Our potential treatment paradigm is unique: Viaskin is an electrostatic patch in development that activates the immune system through the skin, which may offer easy-to-use, self-administered and non-invasive treatments to patients.

Viaskin Aims to Unlock the Powerful Immune Properties of the Skin

Our investigational treatment is based on epicutaneous immunotherapy, or EPIT. This potential new class of immunotherapy works by delivering biologically active compounds to the immune system through intact skin using the Viaskin platform.

For those patients facing life-threatening food allergies, EPIT aims to desensitize them to harmful allergens by delivering compounds in small quantities into the outer layers of the skin.

EPIT also offers a potentially strong safety profile because of how it works via the skin. Safety for food-allergic patients is paramount since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening reactions, including anaphylactic shock.

We are developing the Viaskin technology platform to help improve the lives of patients suffering from peanut and other food allergies. Programs in development include late stage clinical trials of Viaskin Peanut and Viaskin Milk, as well as pre-clinical studies of Viaskin Egg.

DBV’s robust development program includes ongoing clinical trials of Viaskin Peanut and Viaskin Milk and pre-clinical development of Viaskin Egg.

Viaskin’s potential to unlock the immune properties of skin makes it a promising therapeutic approach beyond food allergies. DBV is investigating other areas of significant unmet medical need, including Eosinophilic Esophagitis (EoE), vaccines, inflammatory conditions and autoimmune diseases.